AZ-BMS diabetes combo recommended for EU, but will corporate combo survive?
This article was originally published in Scrip
The recommended approval in Europe of a metformin/dapagliflozin drug combination by the CHMP on 21 November may yet prove to be an allegory for the way in which the business relationship between the drug's sponsors, AstraZeneca and Bristol-Myers Squibb, plays out over the coming months. The anticipated approval that would follow the recommendation could tip the balance of power in the relationship between the two companies in favour of AstraZeneca.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.